MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results

被引：0
|
作者：
Alvarez, R. H.
DeMichele, A.
Mailliez, A.
Benaim, E.
Fingert, H.
Schusterbauer, C.
Zhang, B.
Melichar, B.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Abramson Canc Ctr, Philadelphia, PA USA
[3] Ctr Oscar Lambret, F-59020 Lille 59, France
[4] Millennium Pharmaceut Inc, Cambridge, MA USA
[5] Fak Nemocnice Olomouc, Onkol Klin, Olomouc, Czech Republic
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P6-10-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-02
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors
    Zhou, Xiaofei
    Pusalkar, Sandeepraj
    Chowdhury, Swapan K.
    Searle, Shawn
    Li, Yuexian
    Ullmann, Claudio Dansky
    Venkatakrishnan, Karthik
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 666 - 673
  • [32] Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results.
    Falchook, Gerald Steven
    Goff, Barbara Ann
    Kurzrock, Razelle
    Gray, Heidi J.
    Martin, Lainie P.
    Coleman, Robert L.
    Liu, Hua
    Zhou, Xiaofei
    Benaim, Ely
    Schilder, Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors
    Shah, Hiral A.
    Fischer, James H.
    Venepalli, Neeta K.
    Danciu, Oana C.
    Christian, Sonia
    Russell, Meredith J.
    Liu, Li C.
    Zacny, James P.
    Dudek, Arkadiusz Z.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 413 - 420
  • [34] A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis
    Gangat, Naseema
    Swords, Ronan T.
    Stein, Brady Lee
    Marinaccio, Christian
    Watts, Justin M.
    Frankfurt, Olga
    Altman, Jessica K.
    Al-Kali, Aref
    Zblewski, Darci
    Gurbuxani, Sandeep
    Wen, Jeremy Q.
    Tapia, Roberto
    Barath, Stephanie
    Graf, Amy
    Handlogten, Amy
    Dinh, Yvonne Trang
    Englund, Kristen
    Patel, Shradha
    Bodes, Orlando
    Ogden, Jillian
    Giles, Francis J.
    Tefferi, Ayalew
    Crispino, John D.
    BLOOD, 2017, 130
  • [35] Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Cervantes, Andres
    Elez, Elena
    Roda, Desamparados
    Ecsedy, Jeffrey
    Macarulla, Teresa
    Venkatakrishnan, Karthik
    Rosello, Susana
    Andreu, Jordi
    Jung, JungAh
    Sanchis-Garcia, Juan Manuel
    Piera, Adelaida
    Blasco, Inma
    Manos, Laura
    Perez-Fidalgo, Jose-Alejandro
    Fingert, Howard
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4764 - 4774
  • [36] Effects of rifampin, a strong metabolic enzyme inducer, on the pharmacokinetics (PK) of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), in patients with advanced solid tumors or lymphomas
    Zhou, X.
    Pant, S.
    Sarantopoulos, J.
    Patel, M.
    Nemunaitis, J.
    Lockhart, A. C.
    Zhang, B.
    Bargfrede, M.
    Muehler, A.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S76 - S76
  • [37] MLN8237 (ALISERTIB), AN INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING CASTRATION-RESISTANT PROSTATE CANCER (CRPC) RECEIVING A STANDARD DOCETAXEL REGIMEN: PRELIMINARY PHASE 1 RESULTS
    Hahn, N. M.
    Sarantopoulos, J.
    Higano, C.
    Zhou, X.
    Zhang, B.
    Leonard, E. J.
    Benaim, E.
    Graff, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 303 - 304
  • [38] TAK-733, an investigational, selective MEK1/2 inhibitor, in combination with alisertib (MLN8237), an investigational, selective Aurora A kinase inhibitor is tolerated and results in additive to synergistic antitumor activity: Results from In Vivo Studies
    Fabrey, Robyn
    O'Connell, Shawn
    Stanton, Andrew
    Chakravarty, Arijit
    Gangolli, Esha
    Ecsedy, Jeffery
    Zarycki, Jodi
    Vincent, Patrick
    CANCER RESEARCH, 2012, 72
  • [39] Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)
    Friedberg, Jonathan
    Mahadevan, Daruka
    Jung, JungAh
    Persky, Daniel O.
    Lossos, Izidore S.
    Danaee, Hadi
    Zhou, Xiaofei
    Leonard, E. Jane
    Bernstein, Steven H.
    BLOOD, 2011, 118 (21) : 46 - 46
  • [40] Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC)
    Sarantopoulos, John
    Hahn, Noah M.
    Higano, Celestia S.
    Leonard, E. Jane
    Zhang, Bin
    Zhou, Xiaofei
    Ullmann, Claudio Dansky
    Graff, Julie Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345